scispace - formally typeset
Y

Yang Li

Researcher at Harbin Medical University

Publications -  28
Citations -  847

Yang Li is an academic researcher from Harbin Medical University. The author has contributed to research in topics: Arthritis & Diabetic cardiomyopathy. The author has an hindex of 11, co-authored 25 publications receiving 433 citations.

Papers
More filters
Journal ArticleDOI

Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy.

TL;DR: Investigating whether metformin can inhibit the NLRP3 inflammasome by activating the AMPK/mTOR pathway in diabetic cardiomyopathy found that it can activate AMPK, thus improving autophagy via inhibiting the mTOR pathway and alleviating pyroptosis in DCM.
Journal ArticleDOI

Monocytes in rheumatoid arthritis: Circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis.

TL;DR: The identity of monocytes, the antigenic expression on monocyte surface and their cytokines role in RA are enlightened, and monocytes are the circulating precursors of macrophages and osteoclasts in RA.
Journal ArticleDOI

Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy.

TL;DR: Findings indicate that melatonin produces an antifibrotic effect via inhibiting lncR‐MALAT1/miR‐141‐mediated NLRP3 inflammasome activation and TGF‐β1/Smads signaling, and it might be considered a potential agent for the treatment of DCM.
Journal ArticleDOI

A Novel Circular RNA Mediates Pyroptosis of Diabetic Cardiomyopathy by Functioning as a Competing Endogenous RNA.

TL;DR: This study identified that hsa_circ_0076631, named caspase-1-associated circRNA (CACR), was increased both in high-glucose-treated cardiomyocytes and in the serum of diabetic patients, and elucidated that CACR might be a novel therapeutic target via the C ACR/miR-214-3p/casp enzyme-1 pathway in DCM.
Journal ArticleDOI

LncRNA H19 promotes triple-negative breast cancer cells invasion and metastasis through the p53/TNFAIP8 pathway.

TL;DR: Insight is provided into a novel mechanism of lncRNA H19 in tumorigenesis and metastases of breast cancer and H19/p53/TNFAIP8 axis is demonstrated as a promising therapeutic target for breast cancer, especially for TNBC.